Clinical trial

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

NCT02443337

Study summary

ClinicalTrials.gov

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention LY3023414 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Necitumumab Normalized identity: necitumumab View linked drug · Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2015-07-01

PhasePHASE2

Conditions

Non-small Cell Lung Cancer Metastaticunresolved

Interventions

LY3023414DRUG

NecitumumabDRUG · verified · RxNorm: necitumumab

Sponsors & collaborators

Eli Lilly and Companylead sponsor

SCRI Development Innovations, LLCcollaborator

Mapped research locations

NashvilleTennessee, United States2 CincinnatiOhio, United States1 OrlandoFlorida, United States1 Kansas CityMissouri, United States1 CharlottesvilleVirginia, United States1 Fort WorthTexas, United States1 West Palm BeachFlorida, United States1 St. PetersburgFlorida, United States1 Fort MyersFlorida, United States1 ChattanoogaTennessee, United States1 MobileAlabama, United States1 ChandlerArizona, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02443337 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.